Sanofi Consumer Healthcare India Limited (BSE: 544250 | NSE: SANOFICONR) has reported robust financial results for the third quarter of FY2025, with revenue surging 46% year-on-year to ₹2,339 million and net profit rising 40% to ₹629 million. The growth was driven by a sharp rebound in exports and steady domestic sales. Export sales grew more than tenfold during the quarter owing to a low base, while domestic sales recorded a 20% increase. For the nine-month period, the company posted revenue of ₹6,274 million, up 13% year-on-year, with profit after tax increasing by 27%.
Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited: “Our third-quarter results reflect the strength of our diversified portfolio driving sustained growth momentum this quarter. The domestic business demonstrates good performance, with exports providing additional impetus to revenue growth. All our voluntarily recalled products have successfully re-established their market presence within the year. Anchored in science and guided by purpose, we remain committed to making self-care simpler, more accessible and more effective for every consumer.”
In Kolkata, Sanofi’s portfolio, including popular brands like Allegra®, Combiflam®, and DePURA®, continues to see strong traction, particularly in the pain care and digestive wellness segments. Retailers report rising demand as consumers increasingly turn to trusted over-the-counter products for daily health needs.
